RT Journal Article
SR Electronic
T1 Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.13.20087734
DO 10.1101/2020.05.13.20087734
A1 Andrew G. Weber
A1 Alice S. Chau
A1 Mikala Egeblad
A1 Betsy J. Barnes
A1 Tobias Janowitz
YR 2020
UL http://medrxiv.org/content/early/2020/05/15/2020.05.13.20087734.abstract
AB Background Mechanically ventilated patients with coronavirus disease 2019 (COVID-19) have a mortality of 24-53%, in part due to distal mucopurulent secretions interfering with ventilation. Dornase alfa is recombinant human DNase 1 and digests DNA in mucoid sputum. Nebulized dornase alfa is FDA-approved for cystic fibrosis treatment. DNA from neutrophil extracellular traps (NETs) contributes to the viscosity of mucopurulent secretions. NETs are found in the serum of patients with severe COVID-19, and targeting NETs reduces mortality in animal models of acute respiratory distress syndrome (ARDS). Thus, dornase alfa may be beneficial to patients with severe COVID-19—acting as a mucolytic and targeting NETs. However, delivery of nebulized drugs can aerosolize SARS-CoV-2, which causes COVID-19, increasing the infection risk for staff. Here, we report a single center case series where dornase alfa was administered through an in-line nebulizer system to minimize risk of virus aerosolization.Methods Demographic, clinical data, and outcomes were collected from the electronic medical records of five mechanically ventilated patients with COVID-19—including three requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO)—treated with nebulized in-line endotracheal dornase alfa co-administered with albuterol (used to increase delivery to the alveoli), between March 31 and April 24, 2020. Data on tolerability and responses, including longitudinal values capturing respiratory function and inflammatory status, were analyzed.Results Following nebulized in-line administration of dornase alfa with albuterol, the fraction of inspired oxygen requirements was reduced for all five patients. All patients remain alive and two patients have been discharged from the intensive care unit. No drug associated toxicities were identified.Conclusions The results presented in this case series suggest that dornase alfa will be well-tolerated by critically ill patients with COVID-19. Clinical trials are required to formally test the dosing, safety, and efficacy of dornase alfa in COVID-19, and two have recently been registered (NCT04359654 and NCT04355364). With this case series, we hope to contribute to the development of management approaches for critically ill patients with COVID-19.Competing Interest StatementMikala Egeblad is receiving lonodelestat from Santhera for preclinical studies, but has no financial relationship with Santhera.Clinical TrialClinicalTrials.gov Identifer: NCT04387786 The study is a retrospective case study.Funding StatementThis work was supported by the William C. and Joyce C. ONeil Charitable Trust. In addition, M.E. and T.J. are supported by NIH grant 5P30CA045508-30. B.J.B. is supported by NIH grant 1R01AR076242-01 and DOD LRP W81XWH-18-1-0674. A.S.C. was supported by The Primary Immune Deficiency Treatment Consortium (U54 AI 082973), funded jointly by NCATS (write out) and the National Institute of Allergy and Infectious Diseases (NIAID).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included within the article.LIST OF ABBREVIATIONSARDSacute respiratory distress syndromeBIDbis in die (twice daily)COVID-19coronavirus disease 2019CRPC-reactive proteinddayFiO2fraction of inspired oxygengttguttae (intravenous drip)ICUintensive care unitLDHlactate dehydrogenaseMRSAmethicillin-resistant Staphylococcus aureusnDA+Anebulized dornase alfa plus albuterolNETsneutrophil extracellular trapsPaCO2arterial partial pressure of carbon dioxideSARS-CoV-19severe acute respiratory syndrome coronavirus 2VV-ECMOveno-venous extracorporeal membrane oxygenation